Northwestern Mutual Wealth Management’s Monopar Therapeutics MNPR Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Buy	+1,350	New	+$83.6K	﹤0.01%	2187

Other funds holding MNPR

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Northwestern Mutual Wealth Management's MNPR Position: Q2 2026 in Review

Northwestern Mutual Wealth Management opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 1,350 shares worth $125K. The stake represents ﹤0.01% of the portfolio and ranks #2187 among its holdings.

96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

Northwestern Mutual Wealth Management held 1,350 shares of Monopar Therapeutics worth $125K as of Q2 2026.
Monopar Therapeutics was a new Northwestern Mutual Wealth Management position in Q2 2026.
Monopar Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #2187 holding.
96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.